<DOC>
	<DOCNO>NCT00957541</DOCNO>
	<brief_summary>The purpose study evaluate performance new sensor-based diagnostic feature , implement cardiac resynchronization therapy ( CRT ) device . This trial study effectiveness diagnostic feature detect heart failure event medically stable , ICD-indicated , congestive heart failure patient .</brief_summary>
	<brief_title>Evaluation Diagnostic Feature Cardiac Resynchronization Therapy ( CRT ) Device</brief_title>
	<detailed_description>The purpose study evaluate performance new sensor-based diagnostic feature , implement cardiac resynchronization therapy ( CRT ) device . This trial study effectiveness diagnostic feature detect heart failure event medically stable , ICD-indicated , congestive heart failure patient . The ability diagnostic feature 'detect ' 'predict ' heart failure event study .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Subject eligible implantation CRTD device accord current available guideline cardiac resynchronization therapy Subject severe heart failure ( NYHA Class III IV ) Subject experience least one heart failure event within six month prior enrollment Subject continue heart failure symptom despite receive optimal medical therapy Schedule implant PARADYM CRTD ( Model 8770 ) Subject sign date informed consent form Any contraindication standard cardiac pace Any contraindication ICD therapy Abdominal implantation site Hypertrophic obstructive cardiomyopathy Acute myocarditis Unstable coronary symptom ( unstable angina myocardial infarction ) within last month Recent ( within last month ) plan cardiac revascularization coronary angioplasty Correctable valvular disease primary cause heart failure Mechanical tricuspid valve Receiving continuous intravenous infusion positive inotropic therapy intermittent therapy ( intravenous infusion ) twice per week Heart transplant recipient Renal insufficiency require dialysis Already include another clinical study Life expectancy le 12 month Inability understand purpose study refusal cooperate Inability refusal provide inform consent HIPAA Unavailability schedule followup implanting center Known sensitivity 1mg dexamethasone sodium phosphate ( DSP ) Under guardianship Age le 18 year Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>NYHA Class III IV</keyword>
	<keyword>Implantable Cardiac Defibrillator</keyword>
	<keyword>Cardiac Resynchronization Therapy</keyword>
</DOC>